Joel G. Rurik

TL;DR: This work demonstrates the efficacy of redirected T cell immunotherapy to specifically target pathological cardiac fibrosis in mice and finds that cardiac fibroblasts that express a xenogeneic antigen can be effectively targeted and ablated by adoptive transfer of antigen-specific CD8+ T cells.

TL;DR: A therapeutic approach to generate transient antifibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modified messenger RNA (mRNA) in T cell–targeted lipid nanoparticles (LNPs) was developed.

TL;DR: In this paper, the authors review the immune response to heart injury, its contribution to cardiac fibrosis, and the potential of immune modifying therapies to affect cardiac repair, and propose a new treatment avenue for new treatment avenues for cardiac disease.

TL;DR: In this article , the authors discuss recent studies and emerging research aimed to extend this approach beyond oncology in areas such as cardiometabolic disorders, autoimmunity, fibrosis and senescence.

TL;DR: In this article , an intronic secondary DMR at Grb10 with paternal-specific CTCF binding (CBR2.3) was shown to be indispensable for tissue-specific imprinting of two previously unlinked genes.